Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2022 Results Earnings Conference Call May 9, 2022 4:30 PM ET
Company Participants
Deepankar Roy - Senior Director, Investor Relations
Joseph Payne - President and Chief Executive Officer
Andrew Sassine - Chief Financial Officer
Pad Chivukula - Chief Scientific Officer and Chief Operating Officer
Conference Call Participants
Yasmeen Rahimi - Piper Sandler
Evan Wang - Guggenheim Partners
Nick Abbott - Wells Fargo Securities
Yigal Nochomovitz – Citigroup
Kumaraguru Raja - Brookline Capital Markets
Steven Seedhouse - Raymond James & Associates
Thomas Yip - H.C. Wainwright & Co.
Operator
Good day. And welcome to the Arcturus Therapeutics First Quarter 2022 Earnings Call. Today's conference is being recorded.
At this time, I would like to turn the conference over to Deepankar Roy, Senior Director of Investor Relations. Please go ahead, sir.
Deepankar Roy
Thank you, James. Good afternoon and welcome to Arcturus Therapeutics First Quarter 2022 Financial Results and Corporate Update Call. Thank you all for joining us.
Today's call will be led by Joseph Payne, President and CEO, and Andy Sassine, our CFO. Dr. Pad Chivukula, our CSO and COO, will join for the Q&A session.
Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation from Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance and achievements to differ materially from those expressed or implied by the statement.
Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our Forms 10-Q and 10-K filed with the SEC.
In addition, any forward-looking statements represent our views only as of the date such statements are made, May 9, 2022. Arcturus specifically disclaims any obligation to update such statements to reflect future information, events or circumstances.
With that, I'll now turn the call over to Joe.
Joseph Payne
Hey. Thank you, Deepankar. Good afternoon to all. Thank you for joining Arcturus' Q1 quarterly call. My comments today initially capture a list of summary points for the quarter and I'll follow that up with additional detail per program before I turn the time over to Andy for financial updates.
This quarter has been highlighted by several key achievements. Indeed, we've made significant progress advancing our pipeline of mRNA-based vaccines and therapeutics. So, let's begin with ARCT-154. This is our most advanced COVID vaccine candidate that has shown impressive activity against SARS-CoV-2, both as a primary vaccine and as a booster. We're pleased with the promising results coming from a Phase 1/2 study evaluating ARCT-154 and its potential as a booster in individuals primed with Comirnaty. But the boost with ARCT-154 generated high booster numbers. These are the geometric mean fold rises or GMFRs in neutralizing antibody titers and we'll share more of those results in a moment.